Clasado Biosciences has announced that its flagship prebiotic ingredient, Bimuno GOS, has now surpassed 130 published scientific studies backing its efficacy.
The developer of prebiotic ingredients and solutions for the gut microbiome said in a release that Bimuno GOS is proven to support gastrointestinal, immune, cognitive and metabolic health, as well as enhance sleep, sports nutrition and nutrient absorption.
This solidifies its position as the most comprehensively studied prebiotic galactooligosaccharide (GOS) ingredient available to health and nutrition formulators.
The most recent research backing the ingredient was published in the journal Metabolites, highlighting that Bimuno GOS achieves a proven bifidogenic effect with ultra-low doses, requiring only 380 mg of active GOS daily.
This discovery opens new opportunities for capsule and tablet formulations, especially in limited spaces.
Why this matters
Consumer interest in gut health is rapidly growing across global markets.
According to McKinsey studies, more than 80% of consumers in China, the UK and the US recognise the importance of gut health. Additionally, more than 50% of these consumers expect to prioritise it in the coming years.
As a result, the demand for scientifically proven ingredients is at an all-time high. Bimuno GOS provides a comprehensive evidence base, giving formulators a reliable foundation for creating products that address both long-term consumer health goals and current market trends.
Dr Lucien Harthoorn, R&D Director at Clasado, commented: "Reaching 130 publications represents another significant milestone in our scientific journey."
"What makes this achievement particularly special is the diversity of our latest research, with further studies due to be published this year. From demonstrating efficacy at capsule-compatible doses to proving benefits for elite athletes, we're continually expanding what's possible with Bimuno GOS."
These studies show how our ingredient can meet the evolving needs of formulators across different product formats and health categories.
Per Rehné, CEO at Clasado, added: "This milestone reflects a strong period of progress for Clasado, including Bimuno GOS surpassing 100 available health claims across multiple global markets."
"Our commitment to advancing prebiotic science through rigorous research continues to set us apart very clearly in the marketplace."
With more than 130 publications now supporting Bimuno GOS, including more than 25 clinical trials, we're providing our formulation partners with unparalleled scientific substantiation for their product development and marketing claims.